At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,717 enrolled
Drug / intervention
leuprolide (Lucrin/Lucrin-Tri-depot)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer
In Brief
An observational study evaluating leuprolide (Lucrin/Lucrin-Tri-depot) for Prostatic Neoplasm. Completed, enrolled 2,717 participants across 135 sites in 2 countries.
Detailed Summary
Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasm
CountriesBelgium, Luxembourg
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
First PostedMar 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedMar 5, 2010
Enrollment StartJun 1, 2004
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 16.3 years ago
Interventions
leuprolide (Lucrin/Lucrin-Tri-depot)drug
Subcutaneous or intramuscular administration for all participants